Mental Health Clinician Volume 1: Issue 12

Select Issue

The 15th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists

PharmD, BCPP

Tampa, Florida was bustling with over 500 psychiatric and neurologic pharmacists last month. The 15^th Annual CPNP Meeting took place April 29^th through May 2^nd, 2012, at the Tampa Marriott Waterside. This meeting was full of wonderful and innovative programming and networking opportunities that inspired psychiatric and neurologic pharmacists to continue to improve their practices. This issue recaps some of the topics covered at the meeting and provides highlights from the meeting. Read articles from some of the Annual Meeting speakers as well as articles by other experts in our field.

Many of the

Download PDF

Twice a day dosing of aripiprazole

PharmD, BCPP

DOI: 10.9740/mhc.n109226

Despite pharmacokinetic and pharmacodynamic evidence, unconventional dosing is seen in clinical practice. This article reviews data in the use of multiple daily dosing of aripiprazole, and agent with a long half-life that is indicated for once daily dosing.

Download PDF

Clinical Pearl: Levamisole-induced vasculitis with necrosis in chronic cocaine users

PharmD, BCPS

DOI: 10.9740/mhc.n109214

This case reveals an additional risk faced by persons who abuse substances, specifically when such substances are adulterated. Levamisole, often used to falsely extend the quantity of cocaine a person believes he is purchasing, is known to have life-threatening adverse events. In this case, a chronic cocaine user developed vasculitis from impure cocaine.

Download PDF

Educational efforts around medical marijuana: Thoughts to contemplate for patients and providers

PharmD, BCPP

DOI: 10.9740/mhc.n109221

Medical marijuana is one of the hot topics of our time. Between the political battles, potential financial gain, and controversial effects on health, marijuana use is complicated by agendas, biases, and secondary gain from many parties. Sorting through the growing body of evidence can be overwhelming and confusing, often yielding conflicting conclusions and occasionally utilizing bad science. In struggling to figure out this complex issue, I began searching for a perspective that would be useful to my patients and colleagues. I wanted to keep the attention on the individuals I serve and avoid a hyper-focus on debating the evidence or

Download PDF

FDA safety alerts: Getting the response right!

PharmD, BCPP and

PharmD, BCPP

DOI: 10.9740/mhc.n109342

The Food and Drug Administration (FDA) has issued more than 350 safety alerts for drugs and biological products, since January 2008.¹ Approximately 12% (40) of these alerts were regarding medications indicated for the treatment of neurologic or psychiatric disorders. FDA safety alerts are intended to improve patient safety by providing the medical community with timely new safety data and actionable information that may impact treatment choices by both healthcare providers and patients. Communication of the safety alert to health care professionals also generally provides a summary of the data that serves as the basis for the alert, although

Download PDF

Research programming - pharmacogenomics

PharmD, BCPP

DOI: 10.9740/mhc.n109224

Over the past few years, collaboration between the CPNP Research and Program Committees has resulted in high quality, membership driven research programming at the Annual Meeting. Input is requested from all CPNP committees but this collaboration, in particular, has led to the development of focused programming fulfilling a need for members who either work primarily in a research setting or want to keep abreast of the ever-changing field of psychopharmacology research. One of the logistical difficulties of this type of collaboration is the CPNP programming timeline. It is not long after the Annual Meeting that the following year's offerings are

Download PDF

Management of metabolic syndrome, a cookbook no longer

PharmD, BCPS

DOI: 10.9740/mhc.n109222

The Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) were published in September 2002 (with update in 2004) and December 2003 respectively.¹ ² Over the past three years clinicians have been anxiously awaiting the update of these guidelines; however, we are still waiting.

The JNC 8 is expected to be released at some point in 2012 according to the National Heart Lung and Blood

Download PDF

The invisible injury

PharmD

DOI: 10.9740/mhc.n109223

Dr. Arlinghaus gave an inspiring session on the neuropsychiatric sequelae of traumatic brain injury. TBIs are on the rise and there is concern that this will become an epidemic of our veteran population. Here, highlights are presented, including some evidence regarding pharmacologic treatments, all of which are considered off-label use.

Kimberly Arlinghaus, MD, presented Management of Neuropsychiatric Sequelae of Traumatic Brain Injury at the 2012 CPNP Annual Meeting. Dr. Arlinghaus commenced her presentation with recognition and tribute for those that have served in the US Armed Forces. In her time as a board-certified psychiatrist with specialization in neurology, Dr. Arlinghaus

Download PDF

Book Review: PDQ (Pretty Darned Quick) Statistics (3rd Edition)

Pharm.D., BCPP

DOI: 10.9740/mhc.n108963

CPNP members maintain a suggested reading list to provide information on peer recommended resources and convenient access to the highest quality neuropsychopharmacology publications. A reminder that if you shop with CPNP, by following the links below to Amazon, a small commission will be paid to CPNP which helps to financially support our mission to improve the minds and lives of individuals with psychiatric and/or neurologic disorders.

You can help grow this list of resources by suggesting a book.

BOOK:PDQ (Pretty Darned Quick) Statistics (3rd Edition)

PRODUCT DESCRIPTION:

PDQ Statistics, Third Edition, offers an expert overview

Download PDF

CPNP ratcheting up to pursue payment for services

Pharm.D., M.S., BCPP

DOI: 10.9740/mhc.n109303

By all reasonable measures, CPNP members have been at work literally around the clock since returning from Tampa. The burst of energy and enthusiasm that is being demonstrated around the broad rubric of the legislative arena is particularly noteworthy. As those of you who attended the annual meeting are aware, from participating in the pre-meeting workshop, the roundtables, town hall, and other venues at the annual meeting, there is a flurry of action going on around defining the next steps from various groups at CPNP to obtain a mechanism for payment for services. To this end, CPNP has retained the

Download PDF

CPNP Announcement

DOI: 10.9740/mhc.n108964

A SIT DOWN WITH INCOMING CPNP PRESIDENT REX LOTT

On July 1^st, current CPNP President-elect Rex Lott, Pharm.D., BCPP will become president of CPNP. We were fortunate enough to sit down with Dr. Lott at the CPNP annual meeting and discuss his plans and vision for the direction CPNP is going in the coming year and beyond.

Before getting to the pressing interview questions, we'd like to share some information about our incoming president. Dr. Lott has been a practicing psychiatric and neurologic pharmacist for nearly 40 years, having received his BS in pharmacy from Washington State University

Download PDF

The 15th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists

Twice a day dosing of aripiprazole

Clinical Pearl: Levamisole-induced vasculitis with necrosis in chronic cocaine users

Educational efforts around medical marijuana: Thoughts to contemplate for patients and providers

FDA safety alerts: Getting the response right!

Research programming - pharmacogenomics

Management of metabolic syndrome, a cookbook no longer

The invisible injury

Book Review: PDQ (Pretty Darned Quick) Statistics (3rd Edition)

PRODUCT DESCRIPTION:

CPNP ratcheting up to pursue payment for services

CPNP Announcement

A SIT DOWN WITH INCOMING CPNP PRESIDENT REX LOTT

Pharmacist administration of long-acting injectable medications for substance use disorders: A scoping review

Transitions of care: Assessment of adherence to long-acting injectable antipsychotic treatment following discharge from inpatient psychiatry

Use of atypical antipsychotics in individuals with anorexia nervosa

Potential changes impacting psychiatric pharmacy by 2030

A model for timely dissemination of critical information: Clozapine toxicity during the COVID pandemic